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INTRODUCTION
Oral insulin secretagogues are antidiabetic medications that 
have been reported to be causally linked to acute pancreati-
tis (Blomgren & Sudstrom, 2002). Meglitinides are a class of 
insulin secretagogues that act in a glucose-dependent man-
ner to increase pancreatic insulin secretion. They work spe-
cifically by closing adenosine triphosphate (ATP)-dependent 
potassium channels on the β-cell, causing calcium channels 
to open and thereby increasing calcium influx and insulin 
secretion (Stein, Lamos, & Davis, 2013). We will consider the 
effects of a meglitinide analog, repaglinide, by presenting a 
case of likely drug-induced pancreatitis in a patient who was 
started on repaglinide.
CASE PRESENTATION
A 40-year-old male with a medical history of type 2 diabetes 
mellitus, diabetic nephropathy, obesity, and hypertension 
presented to the emergency room with two weeks of severe, 
cramping epigastric pain that radiated to the back. Pain 
was intermittent, severe, and associated with nonbilious, 
nonbloody vomiting and nonbloody diarrhea. The patient 
denied a history of gallstones, hypertriglyceridemia, pan-
creatitis, recent alcohol consumption, fevers, night sweats, 
or weight loss. His medication regimen included metformin 
500 mg PO BID, lisinopril, and metoprolol XL, as well as 
repaglinide 2 mg PO before each meal, which had been ini-
tiated three months earlier for optimal glycemic control. On 
admission, vital signs were temperature of 98.5° F, blood 
pressure of 164/103 mmHg, pulse of 79 beats/minute, and 
respiratory rate of 20 breaths/minute. On abdominal exam, 
the left upper quadrant was tender, without rebound, guard-
ing, or organomegaly. Sclera and skin were anicteric, and 
the remainder of the physical exam was unremarkable. 
Laboratory analysis revealed serum lipase 132 U/L (refer-
ence range 16–58 U/L), amylase 19 U/L (reference range 
34–131 U/L), glucose 423 mg/dL (reference range 74–200 
mg/dL), creatinine 2.5 mg/dL (reference range 0.6–1.2 mg/
dL), calcium 8.9 mg/dL (reference range 8.7–10.0 mg/dL), 
triglycerides 216 mg/dL (reference range <250 mg/dL), and 
HbA1c 12.3%. The remaining laboratory values, including 
white-blood-cell and liver-function tests, were unremark-
able. Imaging was obtained, and abdominal computed 
tomography revealed focal pancreatitis around the head 
and uncinate of the pancreas (Figure 1). Abdominal ultra-
sound showed no evidence of cholelithiasis. The patient was 
diagnosed with acute pancreatitis, made NPO, and given IV 
fluids. An insulin sliding scale, morphine, and ondansetron 
were initiated, and repaglinide was stopped. On hospital 
day 3, the patient’s symptoms resolved, and serum lipase 
and amylase decreased to 21 U/L and 16 U/L, respectively. 
He tolerated a PO diet and was discharged home symptom 
free, on metformin and insulin for glycemic control. 
DISCUSSION 
To date, there are 525 different medications in the World 
Health Organization database that can induce acute pancre-
atitis (Nitsche, Jamieson, Lerch, & Mayerle, 2010). Overall, 
drugs remain a relatively rare causative factor for acute pan-
creatitis, with an incidence between 0.1% and 2% of pan-
creatitis cases (Nitsche et al., 2010). The elderly may be 
especially susceptible to drug-induced pancreatitis due to 
polypharmacotherapy and mixed drug interactions (Nitsche 
et al., 2010). Although we know that activation of trypsin can 
lead to pancreatic autodigestion and, consequently, acute 
pancreatitis, the mechanisms by which certain drugs can 
induce pancreatitis are not known (Blomgren & Sudstrom, 
2002). One theory is that some drugs known to diffuse into 
the pancreas, such as metronidazole, can exhibit a direct 
toxic effect; another is that drugs can lead to an accumula-
tion of toxic metabolites (Nitsche et al., 2010). Unfortunately, 
data for drug-induced pancreatitis remain sparse and most 
are collected from case reports and case-control studies.
A review of the literature shows that some antidiabetic 
medications have been linked to pancreatitis. In a case-
control study, Blomgren and Sudstrom (2002) found an 
increased risk of first-time acute pancreatitis among diabetic 
patients taking glyburide. Insulin and long-term metformin 
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We report a rare case of drug-induced pancreatitis in 
a patient receiving repaglinide antidiabetic therapy. A 
patient with type 2 diabetes mellitus presented with 
severe abdominal cramping, nausea, and vomiting. Three 
months prior to symptoms, repaglinide was added to the 
patient’s current regimen of metformin. The patient was 
diagnosed with acute pancreatitis, treatment was initi-
ated, and repaglinide was discontinued. There was no 
history of pancreatitis or other risk factors such as history 
of gallstones, alcohol abuse, or hypertriglyceridemia. 
The patient reported resolution of symptoms following 
discontinuation of repaglinide. Considering the temporal 
relationship of his symptoms to the addition of repaglinide 
to his existing antidiabetic regimen, this case strongly 
suggests a possible causal link between repaglinide and 
the etiology of acute pancreatitis in this patient.
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use were found to be associated with a decreased risk of 
acute pancreatitis. Long-term sulfonylureas, however, were 
found to increase this risk (Gonzalez-Perez, Schlienger, & 
Garcia Rodriguez, 2010). An analysis of the Food and Drug 
Administration’s adverse-event reporting system by Elashoff, 
Matveyenko, Gier, Elashoff, and Butler (2011) found that 
two glucagon-like peptide-1 (GLP-1) agonists in particular, 
exenatide and liraglutide, carry a sixfold increased risk of 
pancreatitis compared with other therapies. Because of this 
correlation, as seen in several case reports, liraglutide is rec-
ommended to be used cautiously in diabetic patients with 
a history of pancreatitis (Franks, Lee, & George, 2012). In 
animal models, exenatide administration resulted in focal 
proliferation of the exocrine pancreas, which is a well-rec-
ognized component of chronic pancreatitis in humans (Gier 
et al., 2012). Similarly, Matveyenko et al. (2009) showed that 
rats treated with sitagliptin, another GLP-1 agonist, also 
had evidence of increased pancreatic ductal proliferation. 
Although a clear causal relationship between antidiabetic 
medications and pancreatitis has not yet been established, 
studies showing the temporal relationship of drug use and 
symptom onset, combined with resolution of symptoms fol-
lowing drug discontinuation, suggest that such an associa-
tion cannot be excluded.
 
Our patient’s history and clinical findings point to repa-
glinide as the etiologic agent of acute pancreatitis in this 
case. Though we cannot rule out an occult etiology for 
his condition, he had no major risk factors for pancreatitis. 
There are presently no previously reported cases of repa-
glinide-induced acute pancreatitis, and a plausible mecha-
nism for antidiabetic drug–induced pancreatitis has yet to 
be found. Because initiation of repaglinide presumably cor-
responded to an episode of acute pancreatitis in our patient 
and discontinuation resulted in resolution of symptoms, 
repaglinide is strongly suggested to be the cause. This is 
an unusual and rare case of repaglinide-induced pancre-
atitis, and we recommend caution when prescribing repa-
glinide to patients with a history of pancreatitis. Physician 
recognition and patient awareness of possible side effects 
of repaglinide could decrease morbidity and shorten overall 
hospital stays.
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Figure 1 | Focal pancreatitis around the head and uncinate of 
the pancreas. 
